Baxter International, Inc. (BAX) Submits Application for FDA Approval of Recombinant Factor IX for the Treatment of Hemophilia B  
9/4/2012 10:09:46 AM

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced that the company has submitted a biologics license application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for approval of BAX 326, a recombinant factor IX (rFIX) protein being investigated for the treatment and prophylaxis of bleeding episodes for patients over 12 years of age with hemophilia B.